The use of exosomes in regenerative aesthetics represents a conceptual shift. Although stem cells operate using an engraftment and differentiation method, exosomes mediate therapeutic effects through transfer of bioactive molecules that orchestrate regenerative cascades. These tiny particles have evolved from their initial characterization as cellular waste repositories to critical mediators of physiological processes. Laboratory research and clinical trials position exosomes as tailored biological messengers with tissue-specific tropism and immunomodulatory capabilities. Sourcing diversity, ranging from mesenchymal stem cells to immune cells and platelets, imparts distinct molecular signatures that determine therapeutic potential. Contemporary isolation techniques have progressed from ultracentrifugation to more sophisticated approaches yielding variable purity profiles. Regulatory frameworks span Section 351 of the Public Health Service Act governing minimally manipulated preparations, Section 361 therapeutics with specific drug indications, and Federal Food, Drug, and Cosmetic Act-regulated topical formulations, with international approaches varying significantly across jurisdictions. Clinical applications include photoaging remediation, scar remodeling, hair follicle regeneration, wound healing, postprocedure recovery and adipose tissue volumization, with mechanisms encompassing matrix remodeling, neovascularization, and immunomodulation. Emerging evidence supports efficacy in combination with energy-based treatments and microneedling. Future directions include cargo-engineered exosomes, stimuli-responsive release systems, and tissue-specific targeting. Developing GMP-compliant production and unified potency metrics will likely transition exosomes from supplementary components to primary agents in next-generation aesthetic protocols.
Duncan et al. (2025) studied this question.